Astrana Health Inc. (ASTH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 22/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.7% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Healthcare Technology for Providers Stocks Q2 In Review: Astrana Health (NASDAQ:ASTH) Vs Peers
- Why Astrana Health (ASTH) Shares Are Trading Lower Today
- 5 Must-Read Analyst Questions From Astrana Health’s Q2 Earnings Call
- Astrana Health (ASTH) Q2 2026 Earnings Call Transcript
- Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised Guidance ...
- Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates
- Astrana Health Q2 Earnings Call Highlights
- Sector Update: Healthcare Stocks Rise Thursday Afternoon
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Astrana Health Inc..
Full ASTH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.